3 recruiting, 1 active not recruiting, 1 completed, 1 withdrawn. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Recruiting 3, Active not recruiting 1, Completed 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow The Central and Eastern European Gynecologic Oncology Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden Tailored antibiotic and steroid therapy based on the IL-6 value in amniotic fluid obtained by amniocentesis in patients with premature rupture of membranes, Antenatal steroids administration, Neuroprotection - Preterm Premature Rupture of Membranes (PPROM) | Phase 3 | Recruiting | The Central and Eastern European Gynecologic Oncology Group | 138 | 2025-05-01 | 2026-06-18 |
| PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer Standard treatment: Control arm, Experimental arm - Cervical Carcinoma, Adenocarcinoma | Phase 3 | Recruiting | Institut Claudius Regaud | 510 | 2023-12-20 | 2026-10-13 |
| APX005M in Patients With Recurrent Ovarian Cancer APX005M - Ovarian Cancer | Phase 2 | Withdrawn | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 2023-09-07 | 2023-09-11 | |
| Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma Selinexor, Matching Placebo for selinexor - Endometrial Cancer | Phase 3 | Active not recruiting | Karyopharm Therapeutics Inc | 257 | 2023-04-18 | 2026-09-30 |
| Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy No adjuvant therapy, Adjuvant radiotherapy - Cervical Cancer | Phase 3 | Recruiting | The Central and Eastern European Gynecologic Oncology Group | 514 | 2022-06-10 | 2023-09-07 |
| Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] Selinexor, Matching placebo for selinexor - Endometrial Cancer | Phase 3 | Completed | Karyopharm Therapeutics Inc | 263 | 2018-01-05 | 2026-04-13 |
Endometrial Neoplasms (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma (1) · Carcinoma, Adenosquamous (1) · Genital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Ovarian Neoplasms (1) · Preterm Premature Rupture of the Membranes (1) · Uterine Diseases (1) · Uterine Neoplasms (1)
selinexor (2) · 1-dodecylpyridoxal (1) · Amniocentesis (1) · Antibiotic Prophylaxis (1) · Carboplatin (1) · Neuroprotection (1) · Radiotherapy (1) · Radiotherapy, Adjuvant (1) · sotigalimab (1)
Czechia (5) · Italy (3) · Spain (3) · Belgium (2) · Canada (2) · Germany (2) · Greece (2) · Israel (2) · United States (2) · Australia (1) · China (1) · Denmark (1) · France (1) · Georgia (1) · Hungary (1)
David Cibula, prof. (1) · Mansoor R Mirza (1)
PMID 36100282, PMID 37669480, PMID 38627035, PMID 38834399, PMID 40966692
2017 (1)